Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose subcutaneous BAY 1213790 escalation study in healthy male volunteers
NL-OMON46278Completed
- Sponsor
- Bayer
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, single-blind trial of osocimab in venous thromboembolism (VTE) (4 arms), sponsored by Bayer. Primary endpoint: Safety and tolerability. Started Apr 2019; status: completed.
02
Drugs
osocimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON46278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46278.